揭穿
医学
内科学
危险系数
化疗
肿瘤科
卵巢癌
比例危险模型
回顾性队列研究
癌症
对数秩检验
置信区间
外科
作者
Ken Matsukuma,Shin Nishio,Shingo Tasaki,JONGMYUNG PARK,Hiroki Nasu,Teruyuki Yoshimitsu,Kazuto Tasaki,TAKAHIRO KATSUDA,Atsumu Terada,Naotake Tsuda,Sakiko Sanada,Kimio Ushijima
出处
期刊:The Kurume Medical Journal
[The Kurume Medical Journal]
日期:2023-06-30
卷期号:70 (1.2): 29-37
标识
DOI:10.2739/kurumemedj.ms7012004
摘要
Summary: Aim: The relationship between chemotherapy response score (CRS), a widely used response predictor of neoadjuvant chemotherapy-interval debulking surgery (NAC-IDS), and multidrug resistance 1 (MDR1) and CA125 ELIMination rate constant K (KELIM), is undetermined. We evaluated CRS in advanced ovarian cancer patients undergoing NAC and looked for associations between CRS and MDR1 and CA125 KELIM. Our aim was to predict the therapeutic effect of NAC before interval debulking surgery (IDS) by examining its association with CRS.
科研通智能强力驱动
Strongly Powered by AbleSci AI